These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 12505024)
21. Improving HIV treatment step by step. Smart T GMHC Treat Issues; 1996 Aug; 10(8):1-3. PubMed ID: 11363716 [TBL] [Abstract][Full Text] [Related]
22. [Protease inhibitors: a new class of anti-HIV substances]. Dtsch Med Wochenschr; 1996 Aug; 121(34-35):A9-A10. PubMed ID: 8829902 [No Abstract] [Full Text] [Related]
24. Resistance: what are the implications for treatment? Alcorn K IAPAC Mon; 2004 Mar; 10(3):76. PubMed ID: 15108677 [No Abstract] [Full Text] [Related]
25. Time trends in primary HIV-1 drug resistance among recently infected persons. Grant RM; Hecht FM; Warmerdam M; Liu L; Liegler T; Petropoulos CJ; Hellmann NS; Chesney M; Busch MP; Kahn JO JAMA; 2002 Jul; 288(2):181-8. PubMed ID: 12095382 [TBL] [Abstract][Full Text] [Related]
26. Report from San Francisco: The 11th Conference on Retroviruses and Opportunistic Infections (CROI). Antiretroviral therapy: the naïve patient. Gallant JE Hopkins HIV Rep; 2004 Mar; 16(2):1-4. PubMed ID: 15119308 [No Abstract] [Full Text] [Related]
27. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. Roberts NA; Craig JC; Sheldon J AIDS; 1998 Mar; 12(5):453-60. PubMed ID: 9543442 [No Abstract] [Full Text] [Related]
28. Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients". Picchio G; De Meyer S; de Béthune MP AIDS; 2008 Jan; 22(1):165-7. PubMed ID: 18090413 [No Abstract] [Full Text] [Related]
29. Closing in on human immunodeficiency virus-1. Mellors JW Nat Med; 1996 Mar; 2(3):274-5. PubMed ID: 8612219 [No Abstract] [Full Text] [Related]
30. Predicting drug-resistant mutations of HIV protease. Ishikita H; Warshel A Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968 [No Abstract] [Full Text] [Related]
31. Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. Lu Z; Bohn J; Rano T; Rutkowski CA; Simcoe AL; Olsen DB; Schleif WA; Carella A; Gabryelski L; Jin L; Lin JH; Emini E; Chapman K; Tata JR Bioorg Med Chem Lett; 2005 Dec; 15(23):5311-4. PubMed ID: 16203148 [TBL] [Abstract][Full Text] [Related]
32. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694 [TBL] [Abstract][Full Text] [Related]
33. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Wensing AM; van Maarseveen NM; Nijhuis M Antiviral Res; 2010 Jan; 85(1):59-74. PubMed ID: 19853627 [TBL] [Abstract][Full Text] [Related]
34. Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance. Yin PD; Das D; Mitsuya H Cell Mol Life Sci; 2006 Aug; 63(15):1706-24. PubMed ID: 16715409 [TBL] [Abstract][Full Text] [Related]
35. A SOFM approach to predicting HIV drug resistance. Potter RB; Draghici S Pac Symp Biocomput; 2002; ():77-87. PubMed ID: 11928520 [TBL] [Abstract][Full Text] [Related]
36. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states. Hicks C AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598 [TBL] [Abstract][Full Text] [Related]